Loading provider…
- Featuresarrow_drop_down
- Solutionsarrow_drop_down
Loading provider…
Your Medical Sales Assistants that help you easily find, convert and close your ideal providersNeurology Physician in Cincinnati, OH
NPI: 1114190014Primary Practice Location
UNIVERSITY OF CINCINNATI MEDICAL CENTER, LLC
3188 Bellevue Ave, Cincinnati, OH
Primary Employer
University of Cincinnati Physicians Company, LLC
ucphysicians.com
HQ Phone
Get M.D. Aram's Phone Numberphone_androidMobile
Get M.D. Aram's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardOH State Medical License
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99215Established patient office or other outpatient, visit typically 40 minutes | 66 | 77 |
| 2 | 99214Established patient office or other outpatient visit, 30-39 minutes | 38 | 42 |
| 3 | 99213Established patient office or other outpatient visit, typically 15 minutes | 16 | 17 |
Inebilizumab for treatment of neuromyelitis optica spectrum disorder.
Authors: J Tullman, Mark, Zabeti, Aram, Vuocolo, Scott, Dinh, Quinn
Journal: Neurodegener Dis Manag
Publication Date: 2021-09-06
Authors: Mousavi, Pegah, Emadzadeh, Maryam, Karimikhoshnoudian, Bahar, Sahraian, Mohammad Ali, Ghaffari, Mehran, Shaygannejad, Vahid, Payere, Maryam, Baghaei, Ava, Zabeti, Aram, Nahayati, Mohammadali
Journal: Naunyn Schmiedebergs Arch Pharmacol
Publication Date: 2025-06-11
Long-term efficacy and safety of inebilizumab in neuromyelitis optica spectrum disorder: Analysis of aquaporin-4-immunoglobulin G-seropositive participants taking inebilizumab for ⩾4 years in the N-MOmentum trial.
Authors: Mary Rensel
Publication Date: 2021-10-01
Lead Sponsor: The Cleveland Clinic
Collaborators: University of Nottingham
Intervention / Treatment: DRUG: Early Highly Effective Therapies Group, DRUG: Escalation Therapies Group
